The oestrogen receptors (ERα and ERβ) and their role in breast cancer: A review

Breast

Volumn 9, Issue 4, 2000, Pages 194-200

  Girdler, F ^a   Brotherick, I ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGY; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; SIGNAL TRANSDUCTION;

EID: 0033833676     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0203     Document Type: Article

References (47)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions from a new method of treatment, with illustrative cases
2. A two-step mechanism for the interaction of estradiol with rat uterus
3. Overview of the nuclear receptor family
4. Monoclonal-antibodies localize estrogen-receptor in the nuclei of target-cells
5. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
6. Functional domains of the human estrogen-receptor
7. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
8. The estrogen-receptor binds tightly to its responsive element as a ligand-induced homodimer
9. The oestrogen receptor: From perception to mechanism
10. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo
11. Phosphorylation of steroid hormone receptors
12. Steroid hormone receptor phosphorylation: Is there a physiological role?
13. Transcriptional activation by the estrogen-receptor requires a conformational change in the ligand-binding domain
14. Designer estrogens
15. Estrogen receptor variants and mutations
16. Multiple splicing variants of the estrogen receptor are present in individual human breast turners
17. Oestrogen receptor mutants and variants in breast cancer
18. Exon-5 deletion variant estrogen-receptor messenger-Rna expression in relation to tamoxifen resistance and progesterone-receptor-Ps2 status in human breast-cancer
19. The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1
20. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
21. ER beta: Identification and characterization of a novel human estrogen receptor
22. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta
23. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern
24. A novel human estrogen receptor beta: Identification and functional analysis of additional N-terminal amino acids
25. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha
26. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha
27. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro
28. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen-receptor gene
29. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility
30. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta) messenger ribonucleic acid in the wild-type and ER alpha-knockout mouse
31. Generation and reproductive phenotypes of mice lacking estrogen receptor beta
32. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. 1
33. Tamoxifen for early breast cancer: And overview of the randomised trials
34. Antagonistic and agonistic effects of tamoxifen: Significance in human cancer
35. Drug resistance to tamoxifen during breast cancer therapy
36. The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: A flow cytometric study
37. Oestrogen receptor: A stable phenotype
38. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
39. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta
40. Tamoxifen activation of the estrogen receptor Ap-1 pathway - Potential origin for the cell-specific estrogen-like effects of antiestrogens
41. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites
42. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis
43. Coexpression of estrogen receptor alpha and beta: Poor prognostic factors in human breast cancer?
44. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance
45. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
46. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins